FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Murray Mark J.					2. Issuer Name and Ticker or Trading Symbol Arbutus Biopharma Corp [ABUS]							(Check	k all applicat Director	ole)	Person(s) to Issuer 10% Owner Other (specify		ner	
(Last) (First) (Middle) C/O ARBUTUS BIOPHARMA CORP. SUITE 100, 8900 GLENLYON PARKWAY					3. Date of Earliest Transaction (Month/Day/Year) 04/16/2018							x	X Officer (give title Other (specify below) President & CEO					
(Street) BURNABY A1 V5J 5J8					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)															
			Table I - Non-						, Dis	1			1					
				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			5. Amount Securities Beneficiall Owned Fol	y	Form:	Direct II Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)					
Common Shares 04/				04/17/2	2018			M		27,007	A	\$0.354(2)	316,396			D		
			Table II - D							osed of, o			vned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		e	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	1	Transacti (Instr. 4)				
Employee Stock Option (Right to Buy)	\$5.2	04/16/2018		A		418,187		(1)		04/16/2028	Common Stock	418,187	\$0	418,18	37	D		
Employee Stock Option (Right to	\$0.354 ⁽²⁾	04/17/2018		М			27,007	03/30/20	800	03/01/2018 ⁽³⁾	Common Stock	27,007	\$0	0		D		

Explanation of Responses:

- 1. The options vest as follows: 1/3 on April 16, 2019; 1/3 on April 16, 2020; and 1/3 on April 16, 2021.
- 2. Converted from Canadian exercise price of \$0.4444; Cdn\$1.2552=US\$1.00.
- 3. Expiration date extended through termination of blackout period.

/s/ Mark J. Murray

04/17/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.